Literature DB >> 2844451

A specific carrier substance for human corticotrophin releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity.

E A Linton1, C D Wolfe, D P Behan, P J Lowry.   

Abstract

Late gestational maternal plasma contains a carrier substance for corticotrophin releasing factor (CRF-41) with a molecular weight in the region of 40,000. Using gel chromatography and CRF-41 immunoradiometric assay (IRMA), we show that binding of the peptide to its plasma carrier can be disrupted by treatment with urea. The binding capacity of the carrier substance is not saturated, since time-dependent incorporation of synthetic CRF-41 occurs at 4 degrees C. The carrier substance is also present in normal male plasma. It is specific for human CRF-41, not binding to ACTH, GnRH, vasopressin or ovine CRF-41. Most of the high concentration of CRF-41 in late gestational maternal plasma is bound to the carrier. Dilutions of pooled fractions containing carrier-bound CRF-41 after chromatography of maternal plasma had ACTH-releasing activity as did the synthetic peptide. However, the more concentrated chromatographic fractions at the apex of the carrier-bound CRF-41 peak showed reduced bioactivity, indicating that the higher concentrations of carrier in the original maternal plasma could mask the ACTH-releasing activity of CRF-41.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844451     DOI: 10.1111/j.1365-2265.1988.tb01218.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  18 in total

Review 1.  Placental stress factors and maternal-fetal adaptive response: the corticotropin-releasing factor family.

Authors:  Pasquale Florio; Filiberto M Severi; Pasquapina Ciarmela; Giovina Fiore; Giulia Calonaci; Angelica Merola; Claudio De Felice; Marco Palumbo; Felice Petraglia
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

Review 2.  New aspects of placental endocrinology.

Authors:  F Petraglia; L Calzà; G C Garuti; L Giardino; B M De Ramundo; S Angioni
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

3.  Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats.

Authors:  Miriam Goebel; Andreas Stengel; Lixin Wang; Joseph Reeve; Yvette Taché
Journal:  Neuroendocrinology       Date:  2010-12-06       Impact factor: 4.914

Review 4.  The physiological roles of placental corticotropin releasing hormone in pregnancy and childbirth.

Authors:  Murray Thomson
Journal:  J Physiol Biochem       Date:  2012-12-29       Impact factor: 4.158

Review 5.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 6.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

7.  Long-term hypoxia enhances ACTH response to arginine vasopressin but not corticotropin-releasing hormone in the near-term ovine fetus.

Authors:  Charles A Ducsay; Malgorzata Mlynarczyk; Kanchan M Kaushal; Kim Hyatt; Krista Hanson; Dean A Myers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-22       Impact factor: 3.619

8.  Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Authors:  Mark O Huising; Joan M Vaughan; Shaili H Shah; Katherine L Grillot; Cynthia J Donaldson; Jean Rivier; Gert Flik; Wylie W Vale
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

9.  Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons.

Authors:  Hui-Ling Wang; Marisela Morales
Journal:  J Comp Neurol       Date:  2008-07-20       Impact factor: 3.215

10.  Immunosuppressive activity of corticotrophin-releasing factor. Inhibition of interleukin-1 and interleukin-6 production by human mononuclear cells.

Authors:  P Hagan; S Poole; A F Bristow
Journal:  Biochem J       Date:  1992-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.